Saffron

Saffron is a botanical mixture studied chiefly for mood and sleep. A 2019 review of 23 trials found pooled depression and anxiety benefits, but detected publication bias and limited regional diversity [5]. A separate eight-study analysis found no significant difference from fluoxetine; its placebo estimate had a confidence interval reaching zero and substantial heterogeneity. Failure to detect a difference in small trials does not establish antidepressant equivalence [6].

The 2026 GRADE-assessed review included 34 randomized trials and 1,769 adults. Beck Depression Inventory and Beck Anxiety Inventory scores improved, with substantial heterogeneity (I² above 90%). Hamilton Depression Rating Scale, Hamilton Anxiety Rating Scale and Profile of Mood States outcomes did not improve significantly. The authors rated certainty moderate, but this split makes a broad claim of reliable antidepressant efficacy premature [2].

Adjunctive evidence is mixed too. In an eight-week affron trial alongside existing antidepressants, clinician-rated depressive symptoms improved more than placebo, while the self-rated depression scale did not. Quality of life and baseline-adjusted antidepressant side-effect outcomes also showed no significant advantage [7].

Sleep: A four-week affron trial improved insomnia severity, restorative sleep and diary-rated sleep quality, without significant improvement in diary-measured sleep duration or latency [8]. In the six-week Saffr'activ trial, actigraphy showed more time in bed, without significant improvement in total sleep time or sleep efficiency; several questionnaire improvements were within-group changes rather than clear advantages over placebo [3].

A 2025 Safr'Inside trial found a modest insomnia-score advantage when the two saffron arms were pooled. The separate 20 mg and 30 mg comparisons on that primary outcome were not significant after multiple-comparison adjustment. Subjective sleep quality and stress improved, while daytime sleepiness, positive/negative affect and quality of life did not [4].

Cognition: A review of four small trials in Alzheimer's disease or mild cognitive impairment found some cognitive-scale benefits, but insufficient evidence for clinical recommendations. Daily-living improvements were not significant, and these patient studies do not establish memory enhancement in healthy adults [9].

Crocins, crocetin, safranal and picrocrocin are among saffron's constituents. Crocins are glycosides that can be converted to circulating crocetin; their presence in an extract does not imply that unchanged crocin reaches the human brain [1].

Proposed mood and sleep mechanisms include changes in serotonin, GABA and glutamate signalling, with antioxidant and anti-inflammatory pathways also discussed. These explanations come largely from constituent, cell and animal work. Human sleep trials measure outcomes rather than demonstrating a particular receptor mechanism, so saffron should not be described as a clinically established serotonin-reuptake inhibitor or GABA agonist [3].

affron: A stigma extract standardized to more than 3.5% Lepticrosalides in the sleep trial, a combined measure including crocin isomers and safranal [8]. This is not a claim that the product contains 3.5% safranal.

Saffr'activ SAF 3C PIM: The six-week trial described a 15.5 mg preparation supplying 0.9 mg crocins and 0.7 mg safranal. Its measured constituent amounts differ from affron's combined standardization metric [3].

Safr'Inside: The 2025 trial used an extract specified as containing more than 3% crocins, 0.2% safranal, 1% picrocrocin derivatives and 0.1% kaempferol derivatives, assessed by U-HPLC [4]. Milligrams of one named preparation do not establish an equivalent dose of another.

Short studies generally report reasonable tolerability, but adverse events occur. The 2025 sleep trial recorded gastrointestinal discomfort in ten participants on 30 mg, six on 20 mg and four on placebo; no serious adverse events were reported [4]. One participant in the six-week Saffr'activ trial withdrew after evening palpitations that stopped when supplementation stopped [3].

The early depression pilot recorded hypomania in two saffron participants and one imipramine participant, without a significant between-group difference. This is a signal to discuss in people with bipolar disorder or new mood activation, not an estimate of a causal risk [10].

A 2026 safety review found inconsistent adverse-event monitoring and substantial variation in preparations and duration. Small, short trials cannot reliably exclude rare harms, and pregnancy and breastfeeding safety remain inadequately characterized [11].

Anticoagulants and antiplatelet medicines: A case report described nose and gum bleeding during concomitant rivaroxaban and saffron supplementation. One case cannot establish frequency or prove causality, but it supports avoiding an unsupervised combination. The safety review also calls for caution with antiplatelet medicines [11][12].

Antidepressants: Saffron has been tested as an adjunct under study conditions, with inconsistent benefits. That trial does not establish that every antidepressant combination is safe or effective; medication changes or adjunctive use need clinical review [7].